Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PTC299 |
Synonyms | |
Therapy Description |
PTC299 inhibits dihydroorotate dehydrogenase (DHODH), thereby preventing pyrimidine nucleotide synthesis, potentially resulting in decreased MYC expression and VEGFA production, and reduced tumor cell migration and proliferation (PMID: 30352802, PMID: 33496740). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PTC299 | CS-0087039 | PTC299 inhibits dihydroorotate dehydrogenase (DHODH), thereby preventing pyrimidine nucleotide synthesis, potentially resulting in decreased MYC expression and VEGFA production, and reduced tumor cell migration and proliferation (PMID: 30352802, PMID: 33496740). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03761069 | Phase I | PTC299 | Study of PTC299 in Relapsed/Refractory Acute Leukemias | Terminated | USA | 0 |